Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches
This study is currently recruiting participants.
Verified August 2011 by Yale University
Sponsor:
Yale University
Information provided by:
Yale University
ClinicalTrials.gov Identifier:
NCT00660192
First received: April 10, 2008
Last updated: August 3, 2011
Last verified: August 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The hypothesis of this study is that injection of botulinum toxin A into the muscles around the head (frontal, temporal, posterior neck, occipital) can reduce the intensity and frequency of migraine headaches by 50% and more and this effect is even more positive after second treatment.
| Condition | Intervention | Phase |
|---|---|---|
|
Refractory Migraine |
Drug: Botulinum toxin A |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches |
Resource links provided by NLM:
Genetics Home Reference related topics:
familial hemiplegic migraine
Drug Information available for:
OnabotulinumtoxinA
U.S. FDA Resources
Further study details as provided by Yale University:
Primary Outcome Measures:
- 1- Pain Intensity (VAS) 2- Pain frequency [ Time Frame: Quality of life (HIT-6) and MSQ ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 50 |
| Study Start Date: | January 2008 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | July 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: 1
arm 1: compares the effect of Botox with placebo (blinded protocol)
|
Drug: Botulinum toxin A
Series of injections of botulinum toxin totalling 200 to 300 units vs placebo. Final dose is determined by based size of patient and patient neck size.
Other Name: Botox.
|
|
Active Comparator: 2
Arm 2- Open label- every subject receives Botox
|
Drug: Botulinum toxin A
Open label arm with injection of active drug via a series of injections as used in Arm 1 (closed label). A series of intramuscular injections totalling 200 to 300 units of toxin administered.
Other Name: Botox.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adults 18 and older
- Migraine for more than three months, that fail to respond to two or more major anti-migraine drug, meeting criteria of chronic migraine
Exclusion Criteria:
- Age below 18
- Pregnant or may become pregnant
- Disease of neuromuscular junction or drugs that affect N-M junction
- Allergy to Botox
- Previous use of Botox for migraine by similar methodology
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00660192
Contacts
| Contact: Diana Richardson, M.D. | (203) 737-1831 | diana.richardson@yale.edu |
| Contact: Laura Marshall | (203) 785-5420 | laura.marshall@yale.edu |
Locations
| United States, Connecticut | |
| Yale Neurology Clinic, 6C, 40 Temple Street | Recruiting |
| New Haven, Connecticut, United States, 06520 | |
| Principal Investigator: Bahman Jabbari, M.D | |
| Principal Investigator: Bahman Jabbari, M.D. | |
Sponsors and Collaborators
Yale University
Investigators
| Principal Investigator: | Bahman Jabbari, M.D. | Yale University |
More Information
No publications provided
| Responsible Party: | Bahman Jabbari, Professor of Neurology, Yale University School of Medicne |
| ClinicalTrials.gov Identifier: | NCT00660192 History of Changes |
| Other Study ID Numbers: | 0709003056 |
| Study First Received: | April 10, 2008 |
| Last Updated: | August 3, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Yale University:
|
Migraine, refractory migraine, Pain, Botulinum Toxin , Botox |
Additional relevant MeSH terms:
|
Headache Migraine Disorders Pain Neurologic Manifestations Nervous System Diseases Signs and Symptoms Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases |
Botulinum Toxins, Type A Botulinum Toxins Neuromuscular Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Dyskinesia Agents Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 16, 2013